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Abstract
Purpose The aim of this study was to compare patient-reported outcomes (PROs) of BRCA1/2 mutation carriers, either 
after bilateral prophylactic mastectomy (BPM) or during breast surveillance, to improve shared decision-making in their 
cancer risk management.
Methods Unaffected BRCA1/2 mutation carriers at least one year after BPM followed by immediate breast reconstruction 
(BPM-IBR) or one year under surveillance were eligible. After informed consent, the Hospital Anxiety and Depression Scale 
(HADS) and BREAST-Q were administered and compared between the different strategies. PROs were also compared to 
available normative data.
Results Ninety-six participants were analyzed in this study and showed significant differences between strategies in age, age 
at genetic testing, and time since BPM or starting breast surveillance. All HADS scores were below 8 suggesting no signs of 
anxiety or depression in both groups. Higher mean ‘Q-physical well-being’ scores were reported by the surveillance group 
(81.78 [CI 76.99–86.57]) than the BPM group (76.96 [CI 73.16 – 80.75]; p = 0.011). Overall, for both questionnaires better 
scores were seen when compared to age-matched normative data.
Conclusions No signs of anxiety or depression were seen in the surveillance or BPM-IBR group. Slightly better mean 
BREAST-Q scores were seen for the surveillance group in comparison to BPM-IBR, except for ‘Q-psychological well-being’. 
The difference in ‘Q-physical well-being’ was significantly worse for BPM-IBR. Approaches to obtain longitudinal PROs 
and reference values should be explored in the future, which could add value to shared decision-making in regards to breast 
cancer risk management in this specific patient population.
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Abbreviations
PRO(M)  Patient-reported outcome (measures)
BRCA  The BReast CAncer gene
BPM  Bilateral prophylactic mastectomy
IBR  Immediate breast reconstruction
HADS  Hospital Anxiety and Depression Scale
CI  Confidence internal
HRQoL  Health-related quality of life
RRSO  Risk-reducing salpingo-oophorectomy
Introduction
A woman’s lifetime risk of developing breast cancer is 
greatly increased when she inherits a BRCA1 or BRCA2 gene 
mutation. While the general population has a lifetime risk 
of 12% [1], BRCA1 and BRCA2 mutation carriers have a 
cumulative breast cancer risk of, respectively, 72% and 69% 
[2] till 80 years of age.
Breast cancer risk management for BRCA1/2 mutation 
carriers encompass the possibility of intensive breast sur-
veillance aimed at early detection, or bilateral prophylactic 
mastectomy (BPM). BPM has shown a risk reduction up to 
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95% [3-7] and is associated with decreased general and can-
cer-related distress [8, 9]. As BPM is a major, elective and 
irreversible procedure, however, it is also associated with a 
negative impact on health-related quality of life (HRQoL) 
outcomes such as body image, psychosocial-, psychosexual-, 
and physical well-being [8, 10, 11].
The alternative is intensive breast surveillance, consist-
ing of annually alternating mammography and breast MRI, 
and semi-annual clinical breast examination commencing 
at 25 years of age [12]. Carriers who choose surveillance 
might have fewer problems with body image in the psycho-
social- and psychosexual area, but will be confronted with 
difficulties concerning cancer-related distress and the risk 
of breast cancer [13].
Since BPM, either followed by immediate breast recon-
struction (BPM-IBR) or not, and surveillance are both 
validated options with high survival rates [14], the choice 
between them is dependent on the individual woman’s pref-
erences. To facilitate decision-making, it is important to 
fully explain the pros and cons of both options, especially 
when considering preference-based care for which there 
exists more than one clinically appropriate treatment option 
[15]. Therefore, women considering BPM(-IBR) should be 
informed about the impact of prophylactic surgery on not 
only survival and the risk of cancer but on the expected 
HRQoL outcomes as well [8, 15-18].
According to value-based healthcare principles, these 
HRQoL outcomes can be both provider-reported as well as 
patient-reported outcomes (PROs). Since PROs are direct 
assessments from patients, typically collected through vali-
dated questionnaires (i.e., PROMs = patient-reported out-
come measurements), they reflect patients’ quality of life 
or functional status. PRO data is incredibly valuable to get 
insight into long-term HRQoL and can be used as a guide for 
BRCA1/2 mutation carriers in their decision-making process 
in regard to their breast cancer risk management. However, 
little is known about PROs following the choice for either 
BPM or surveillance in BRCA1/2 mutation carriers.
It was hypothesized that PROs differ between women 
choosing BPM(-IBR) and women opting for breast surveil-
lance. This study aimed to compare PROs between BRCA1/2 




A total of 96 unaffected BRCA1/2 mutation carriers, diag-
nosed at the Academic Breast Cancer Centre of the Eras-
mus MC between 2014 and 2017, were included. Female 
BRCA1/2 mutation carriers, aged over 18 years and with 
an adequate understanding of the Dutch language, were 
deemed eligible. Mutation carriers who were at least 1 
year post-BPM-IBR (autologous or implants) were iden-
tified from the electronic health records using operation 
and diagnosis codes. Mutation carriers scheduled for at 
least one year of breast surveillance were approached at 
the surgical oncology outpatient clinic. Mutation carri-
ers were asked to participate until at least 50 participants 
were enrolled in each group. Women with a past history 
of (in situ) breast cancer were excluded. Ethical approval 
was granted by the Institutional Review Board of the 
Erasmus Medical Centre, Rotterdam, The Netherlands 
(MEC-2018–1601).
Procedures
In this cross-sectional study, medical records were retro-
spectively reviewed to collect the following data: BRCA1/2 
mutation status and date of genetic testing, age at genetic 
testing, family history of breast cancer, comorbidities, 
smoking status, family status, time since starting breast 
surveillance, or time since surgery, and—if applicable—
type of surgery performed. Missing data was handled by 
contacting the participant via telephone. For the BPM-
IBR group, eligible women were recruited by telephone 
or mail. Women in the surveillance group were asked to 
participate at the outpatient clinic. Following informed 
consent, two PROM questionnaires were administered: 
the Hospital Anxiety and Depression Scale (HADS) [19] 
and the BREAST-Q version 1.0 (pre-mastectomy mod-
ule for the surveillance group and the post-reconstruction 
module for BPM-IBR) [20]. Both PROMs were web-based 
questionnaires and administered through the software pro-
gram “GemsTracker” [21], an online system for distribut-
ing and collecting surveys. If the questionnaires remained 
uncompleted, a weekly reminder was sent by the system. 
If patients had not responded in four weeks, participants 
were contacted by telephone and asked to complete the 
questionnaires. PROM scores were calculated according 
to the questionnaires’ scoring manuals.
Statistical analysis
All analyses were performed using Statistical Package for 
Social Sciences (SPSS), Version 24.0 (IBM Corporation, 
Armonk, NY, USA). Baseline characteristics were compared 
between women who underwent BPM-IBR versus those 
who chose breast surveillance. Comparisons across both 
groups were made using the Mann–Whitney U test for con-
tinuous variables, and Fisher’s exact test or the Chi-squared 
test, as appropriate, for categorical variables. Two-sided 
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p value < 0.05 was considered statistically significant. In 




Between October 2018 and May 2019, 168 women were 
contacted via telephone, mail or at the outpatient clinic 
(Fig. 1). Of the eligible participants, 143 (85%) women 
responded. Eight (5.6%) responders declined participa-
tion. Of the surveillance group, 22 (25.3%) responders did 
not reply despite verbal consent being obtained at the out-
patient clinic. After informed consent, 55 (63.2%) women 
participated in the surveillance group and 53 (67%) in the 
BPM-IBR group. Three women were excluded from the 
BPM-IBR group: one woman underwent a delayed breast 
reconstruction and the other two due to the absence of a 
BRCA1/2 gene mutation.
Characteristics
A total of 96 participants were included for analysis: 47 
BPM-IBR and 49 breast surveillance participants (Table 1). 
Statistically significant differences were seen between both 
groups in age at study enrollment, age at genetic testing, 
and time since surveillance start or since BPM-IBR. Over-
all, the study population was relatively young: 43% of the 
surveillance group and 45% of the BPM-IBR group were 
aged below 35 years. Approximately 60% of both groups 
had a positive family history for breast cancer in two or more 
relatives. Risk-reducing bilateral salpingo-oophorectomy 
(RRSO) or prophylactic tubectomy were performed in, 
respectively, 45% and 11% of the study population.
PROMs
Table 2 gives an overview of the PROM scores. For both 
groups, all individual HADS scores were below eight, which 
was defined as the upper limit of normal [22]. Slightly better 
mean BREAST-Q scores were seen in the surveillance group 
as compared to the BPM-IBR group, except for the domain 
‘Q-psychological well-being’. In contrast, only the differ-
ence in ‘Q-physical well-being’ was significantly higher 
Fig. 1  Flowchart of study selection process. BPM-IBR, bilateral prophylactic mastectomy followed by immediate breast reconstruction
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in the surveillance group (81.78; CI 76.99–86.57) than the 
BPM-IBR group (76.96; CI 73.16–80.75; p = 0.011).
Obtained HADS scores were compared to normative data 
[22], demonstrating lower scores on both the anxiety and the 
Table 1  Characteristics of 96 BRCA1/2 mutation carriers per type of cancer risk management, n (%)
BPM-IBR bilateral prophylactic mastectomy followed by immediate breast reconstruction, RRSO risk-reducing bilateral salpingo-oophorectomy;
¥ Chi-squared test
§ Mann–Whitney U test
All (n = 96) Surveillance (n = 49) BPM-IBR (n = 47) p value
Mean (SD) age (years)§ 42.4 (10.7) 44.5 (12.0) 40.2 (8.8) 0.046
Mean (SD) age (years) at genetic  testing§ 36.6 (10.3) 38.7 (10.6) 34.3 (9.6) 0.039
Mutation type¥ 0.969
BRCA1 57 (59) 29 (59) 28 (60)
BRCA2 39 (41) 20(41) 19 (40)
Mean (SD) age (years) at start cancer risk  management§ 37.9 (9.8) 38.7 (10.7) 37.1 (8.7) 0.447
Mean (SD) time (years) since start of cancer risk  management§ 4.7 (3.7) 6.1 (4.7) 3.1 (1.2) 0.002
Family history¥ 0.723
0 13 (14) 7 (14) 6 (13)
1 24 (25) 10 (20) 14 (30)
≥ 2 57 (59) 30 (61) 29 (62)
Unknown 2 (2) 2 (4) .0
First degree family history¥ 0.176
0 66 (69) 30 (61) 36 (77)
1 28 (29) 17 (35) 11 (23)
≥ 2 .0 .0 .0
Unknown 2 (2) 2 (4) .0
Second degree family history¥ 0.229
0 63 (66) 32 (65) 31 (66)
1 28 (29) 15 (31) 13 (28)
≥ 2 .0 .0 3 (6)
Unknown 2 (2) 2 (4) .0
Third degree family history¥ 0.617
0 32 (33) 16 (33) 16 (34)
1 31 (32) 14 (29) 17 (36)
 > 2 31 (32) 17 (35) 14 (30)
Unknown 2 (2) 2 (4) .0
Marital status¥ 0.079
Single 8 (8) 1 (2) 7 (15)
Relationship 21 (22) 11 (22) 10 (21)
Married 58 (60) 30 (61) 28 (60)
Unknown 9 (9) 7 (14) 2 (4)
Parity, mean (SD)§ 1.4 (1.0) 1.4 (0.9) 1.5 (1.07) 0.461
Ovarian status¥ 0.147
In situ 31 (32) 16 (33) 15 (32)
RRSO 45 (47) 27 (55) 18 (38)
Tubectomy 11 (11) 3 (6) 8 (17)
Unknown 9 (9) 3 (6) 6 (13)
Smoking status¥ 0.910
Yes 9 (9) 4 (8) 5 (11)
No 73 (76) 31 (63) 42 (89)
Unknown 14 (15) 14 (29) .0
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depression scale in both groups (Fig. 2a). As the mean age of 
our cohort was 42.4 years, normative data of the female age 
category 40–44 years was used for comparison. The norma-
tive data of the preoperative reconstruction module was used 
for the comparison with BREAST-Q scores of both groups 
in our cohort [23, 24]. PROMs were comparable to norma-
tive scores of the BREAST-Q except for the ‘Q-physical 
well-being’ scale, which showed lower scores in the current 
cohort (Fig. 2b).
Discussion
BRCA1/2 mutation carriers are faced with complex deci-
sions within breast (and ovary) cancer risk management. 
Insights into not only cancer risk but also into HRQoL or 
daily functioning as a result of these decisions could improve 
the shared decision-making process and ultimately the care 
delivered. Therefore, this study aimed to obtain and evalu-
ate PROs in BRCA1/2 mutation carriers according to their 
choice of breast cancer risk management (BPM-IBR versus 
breast surveillance).
The PROMs in this study have succeeded in providing 
valuable insights into HRQoL in BRCA1/2 mutation carriers, 
in both the BPM-IBR and the breast surveillance group. The 
Table 2  PROM scores of 96 
BRCA1/2 mutation carriers per 
type of cancer risk management, 
mean (95% CI)
HADS index value: scale from 0–21; BREAST-Q scale from 0 to 100
BPM-IBR bilateral prophylactic mastectomy followed by immediate breast reconstruction, HADS Hospital 
Anxiety and Depression Scale
°Higher scores represent lower quality
§ Higher scores represent higher quality
¥ Mann–Whitney U test
All (n = 96) Surveillance (n = 49) BPM-IBR (n = 47) p  value¥
Mean (95% CI) Mean (95% CI) Mean (95% CI)
HADS°
Anxiety scale 5.36 (4.62–6.09) 5.47 (4.30–6.63) 5.26 (4.30–6.21) 0.691
Depression scale 2.40 (1.80–3.00) 2.51 (1.66–3.36) 2.30 (1.42–3.18) 0.591
BREAST-Q§
Satisfaction with breasts 68.96 (65.09–72.82) 71.51 (65.56–77.47) 66.51 (61.42–71.60) 0.304
Psychosocial well-being 74.08 (70.14–78.01) 70.78 (65.17–76.38) 77.23 (71.67–82.80) 0.143
Physical well-being chest 79.32 (76.29–82.34) 81.78 (76.99–86.57) 76.96 (73.16–80.75) 0.011
Sexual well-being 61.53 (57.87–65.20) 62.82 (57.24–68.41) 60.30 (55.33–65.27) 0.644
Fig. 2  Comparison of PROM scores with normative scores. a HADS 
survey scores versus normative scores [22]. Mean scores with stand-
ard deviations (error bars) for HADS scores. HADS index value: 
scale from 0–21. Higher scores represent lower quality. *Normative 
scores as based on 486 patients (anxiety subscale) and 489 patients 
(depression subscale) [22], presented by gender and age (i.e., female 
and 5-year age group 40–44 years). b BREAST-Q survey scores ver-
sus normative reconstructive scores [23]. Mean scores with standard 
deviations (error bars) for Q-scores. BREAST-Q scale from 0 to 100. 
Higher scores represent better functioning. ^Normative scores as 
based on 1201 participants of the general population [23]
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interpretation of these data was done both separately and in 
comparison to available normative data [22–24].
HADS demonstrated no scores outside normal cut-off 
values on the two scales. Moreover, mean scores observed 
for both groups were quite similar and all reported scores 
were below the upper limit. These observations indicate that 
none of the mutation carriers in the present study reported 
anxiety or depression that reached clinically relevant levels. 
In addition, no significant differences in anxiety or depres-
sion outcomes were observed between women in the surveil-
lance group and the BPM-IBR group.
Overall, slightly better BREAST-Q scores were seen 
for the surveillance group compared to BPM-IBR. The 
surveillance group scored lower on ‘Q-psychological well-
being’, albeit not statistically significant. This difference was 
expected since previous studies have already shown elevated 
levels of psychological distress in women at increased risk 
of developing breast cancer [8, 13]. Only the difference in 
‘Q-physical well-being’ was statistically significant, which 
can be explained by the surgical procedure these women 
have undergone. However, it has been acknowledged that 
not only the statistical significance of the differences in QoL 
questionnaires is important but the clinical relevance of them 
as well [25]. Although there is no consensus yet on clini-
cally relevant BREAST-Q scores, it is generally accepted 
that a difference of 5 points should be considered as a small 
clinical difference, 10 points as moderate, and 20 points as 
a very clinically important difference [26]. There was a dif-
ference of 5–10 points for all BREAST-Q modules except 
for ‘Q-sexual well-being’, which suggests a small clinical 
difference between both groups. PROs should be collected 
longitudinally to evaluate the clinical differences in PROM 
scores over time within both groups.
Of all BREAST-Q subscales, the lowest scores were 
reported for ‘Q-sexual well-being’ by both BPM-IBR and 
breast surveillance women. Previous studies have shown 
that breast cancer surgery may have a negative impact on 
sexual health [27, 28]. The low ‘Q-sexual well-being’ scores 
might also be explained by the high proportion of women 
with a risk-reducing ovarian cancer intervention (RRSO or 
tubectomy). Since RRSO substantially decreases the lev-
els of estrogen and testosterone, it has an effect on quality 
of life and sexual functioning, among other domains, at an 
early age [29, 30]. However, we also compared mean ‘Q-sex-
ual well-being’ scores between women with and without 
RRSO/tubectomy and found slightly higher mean scores in 
the RRSO/tubectomy group (i.e., 65.04 [60.01–70.07] and 
55.90 [49.43–62.38], respectively). This emphasizes our 
rationale of the impact that breast surgery can have on a 
woman’s sexual health, which is in line with our previous 
publication also showing low ‘Q-sexual well-being’ scores 
in surgical treated breast cancer patients (without a BRCA1/2 
mutation) [31]. Also noteworthy is that only 33.9% of the 
women were treated with hormone replacement therapy 
(n = 8 in the BMP-IBR and n = 11 in the surveillance group) 
(data not shown).
Available normative data for the HADS were derived 
from the Epidemiology of Functional Disorders (EpiFunD) 
Study [22] and normative data for the BREAST-Q from the 
Army of Women community [23]. When comparing the 
PROM scores of our cohort with the normative data, one 
must take into account that the normative data were obtained 
in the United Kingdom (HADS) and the United States 
(BREAST-Q). Due to cultural differences between these 
countries and the Netherlands, this data does not entirely 
reflect normative scores for Dutch women. However, similar 
Q-scores were seen when comparing the current cohort with 
Dutch cohorts [27, 32]; i.e., overall better scores except for 
‘Q-psychical well-being’. HADS scores were not available 
within these cohorts.
Significant differences in patient characteristics existed 
between both groups, suggesting a possible treatment indi-
cation bias. Available data on the impact of patient charac-
teristics on a woman’s decision to undergo BPM vary. Most 
studies show that age at genetic testing does not significantly 
affect the choice for BPM [8, 13, 15, 33], which is in opposi-
tion to our findings. On the other hand, no significant differ-
ences in family history, ovarian status, marital status, and 
parity existed between both groups, in contrast to other stud-
ies showing that these factors do have a significant impact 
on the choice for BPM [10, 13, 33-35]. However, due to 
the retrospective design of this pilot study, baseline (anxi-
ety) scores could not be obtained. Women may experience 
physical- and psychological trauma associated with being 
diagnosed with a BRCA1/2 mutation, which will affect their 
HRQoL. Thus, changes in PROs before and after diagnosis 
are to be expected, which emphasizes the necessity of PRO 
collection at baseline.
The significant differences in age at study enrollment, 
age at genetic testing, and the time since BPM-IBR or 
starting breast surveillance could be explained by the man-
ner in which women were selected. Eligible participants 
for the BPM-IBR group were found through a search in 
the electronic health record. The search was thereby lim-
ited by year of surgery, namely between 2014 and 2017. 
Gene mutation carriers scheduled for breast surveillance 
were asked to participate at the outpatient clinic. No lim-
itations on patient inclusion was set for this group and 
could, therefore, be completed before 2014. Although the 
duration of the inclusion period was over 6 months and 
all BRCA1/2 mutation carriers were scheduled for follow-
up every 6 months during their surveillance, a potential 
selection bias could have been introduced. Moreover, 
the time since the start of cancer risk management sig-
nificantly differed between both groups (6.1  years for 
surveillance versus 3.1 years for BPM-IBR, p = 0.002), 
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and time since BMP-IBR was relatively short. Previous 
studies have shown that psychological outcomes as well 
as coping strategies change over time [8, 13] [13]. Cop-
ing strategies represent cognitive and behavioral efforts 
to deal with stressful encounters [36]. Effects of coping 
can differ depending on the duration and controllability 
of the stress factor. As women in our cohort did not have 
a history of breast cancer (consistently favorable results 
during their surveillance), long-term breast cancer-related 
distress might decrease as a consequence of ‘underestimat-
ing’ their breast cancer risk [13]. This observation may 
be a possible explanation for the low distress and anxiety 
levels in our cohort. Another possible explanation for the 
low scores is potential selection bias, as the women who 
experienced increased levels of depression might have 
been less likely to participate.
We did not find that women in the BMP-IBR group 
were more likely to have a first-degree relative with a his-
tory of breast cancer (35% surveillance versus 23% BPM-
IBR, p = 0.176), which is in contrast to what others have 
reported [33, 37].
Intuitively, it would seem that women with a BRCA1 
mutation would most likely be the ones to consider BPM 
as they have a higher breast cancer risk than BRCA2 muta-
tions [2]. Moreover, a previous study with 5,889 Dutch 
BRCA1/2 mutation carriers showed that, compared to 
breast surveillance, BPM was associated with lower mor-
tality for BRCA1 mutation carriers, whereas for BRCA2 
mutation carriers breast cancer-specific survival rates were 
similar between BPM and breast surveillance [38]. In our 
cohort, however, there were no differences in the percent-
age of BRCA1 carriers in the BPM-IBR group compared 
to the surveillance group. The observations that BPM 
was associated with lower mortality rates than surveil-
lance for BRCA1 and similar breast cancer-specific sur-
vival for BRCA2, underscore the importance of counseling 
BRCA1/2 mutation carriers on their choice between breast 
surveillance and BPM. Knowledge of patient-reported 
HRQoL outcomes can be valuable in facilitating this 
choice.
Limitations include the relatively small sample size and 
the retrospective study design. The power was limited due 
to the small study population. Longitudinal PRO collection 
and comparison with baseline PROM scores are needed 
when striving to showcase the influence of different risk 
management strategies [13, 15]. However, the retrospective 
evaluation of PROs does provide the necessary insight into 
(case-mix) factors possibly associated to PROs, and their 
inclusion for predictive modeling.
Multiple PROM instruments are available nowadays. 
Only two questionnaires were selected in this study. HADS 
was chosen since it is a short questionnaire and the most 
extensively validated scale for screening emotional distress 
in cancer patients [39], while BREAST-Q was chosen 
since it is a validated breast-specific instrument that is 
used worldwide. Razdan et al. [15] evaluated PROs after 
BPM and concluded that generic instruments were not 
sensitive enough to measure physical and mental changes 
related to specifically BPM, either followed by (imme-
diate) breast reconstruction or not. The use of a breast-
specific instrument (e.g., BREAST-Q) was recommended. 
We support this recommendation combined with the stand-
ardization of PROMs, since this will provide results that 
are comparable with other similar studies.
Several initiatives of longitudinal PRO collection in 
breast cancer patients have proven to be helpful in daily 
practice and are appreciated by both patients and provid-
ers [40, 41]. The present study provides a first insight into 
PROs in BRCA1/2 mutation carriers following their choice 
for either breast surveillance or BPM-IBR. Collected 
PROs can serve to pave the way for the implementation of 
a value-based healthcare strategy among future BRCA1/2 
mutation carriers at the outpatient clinic. Interpretability 
of the important differences in PRO(M)s is the cornerstone 
to its successful use in individual clinical care, compara-
tive effectiveness research, and regulatory efforts. Knowl-
edge about differences in HRQoL outcomes between BPM 
and surveillance can be used to facilitate shared decision-
making. Informing BRCA1/2 mutation carriers about both 
positive and negative consequences of either BPM-IBR or 
breast surveillance is of great importance for building up 
realistic expectations [9]. Measuring PROs in BRCA1/2 
mutation carriers from gene mutation diagnosis to the sub-
sequent trajectory has the potential to monitor and detect 
changes in psychosocial or physical problems over time. 
Reference PROM scores for the different strategies are 
then essential for the use of PROs at the outpatient clinic 
to personalize and improve the care delivered. Large mul-
ticenter initiatives and prospective PRO collections are, 
therefore, needed to obtain (and narrow down) these refer-
ence scores. Such an initiative is currently pending at our 
institution.
Conclusion
Patient-reported HRQoL outcomes were evaluated in unaf-
fected BRCA1/2 mutation carriers who underwent either 
breast surveillance or BPM-IBR. No signs of anxiety or 
depression were seen in both groups. Slightly better mean 
BREAST-Q scores were seen for the surveillance group 
in comparison to BPM-IBR except for ‘Q-psychological 
well-being’; the difference in ‘Q-physical well-being’ was 
significantly worse for BPM-IBR. A first step was made 
towards value-based healthcare for BRCA1/2 mutation 
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carriers. Future possibilities should be explored to obtain 
reference PROM values, which could add value to the 
shared decision-making process in regard to cancer risk 
management in this specific population.
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